If a even a small fraction of the effort spent on trying and failing to cope with the realities of degenerative aging was spent on the current crop of plausible approaches to build medical biotechnologies that can reverse degenerative aging, then the world would be a much better place.

Aging has an monstrously high economic cost, and is probably the only area of medicine in which the ratio of that cost to the amount spent on R&D to try to reduce that cost is vanishingly small.